Adherence to Tobacco Dependence Treatment Among HIV-Infected Smokers

AIDS and Behavior

Volumn 20, Issue 3, 2016, Pages 608-621

  Browning, Kristine K ^a   Wewers, Mary Ellen ^b   Ferketich, Amy K ^b   Diaz, Philip ^c   Koletar, Susan L ^c   Reynolds, Nancy R ^d  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d YALE UNIVERSITY   (United States)

Author keywords

Adherence; HIV; Participant responsiveness; Smoking cessation; Tobacco dependence treatment

Indexed keywords

NICOTINIC AGENT; VARENICLINE;

ADULT; COMPLICATION; COUNSELING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PATIENT ATTITUDE; PROCEDURES; PSYCHOLOGY; SMOKING CESSATION; STATISTICS AND NUMERICAL DATA; TELEMEDICINE; TELEPHONE; TOBACCO USE DISORDER; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; COUNSELING; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NICOTINIC AGONISTS; PATIENT ACCEPTANCE OF HEALTH CARE; SMOKING CESSATION; TELEMEDICINE; TELEPHONE; TOBACCO USE DISORDER; TREATMENT OUTCOME; VARENICLINE; YOUNG ADULT;

EID: 84959468853     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-015-1059-1     Document Type: Article

References (77)

1. Patel N, Talwar A, Reichert VC, Brady T, Jain M, Kaplan MH. Tobacco and HIV. Clin Occup Environ Med. 2006;5(1):193–207.
2. Diaz PT, King MA, Pacht ER, Wewers MD, Gadek JE, Nagaraja HN, et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med. 2000;132:369–72.
3. Diaz PT, Wewers MD, Pacht E, Drake J, Nagaraja HN, Clanton TL. Respiratory symptoms among HIV-seropositive individuals. Chest. 2003;123(6):1977–82.
4. Kirk GD, Merlo C, O’Driscoll P, Mehta SH, Galai N, Vlahov D, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007;45(1):103–10.
5. Miguez-Burbano MJ, Ashkin D, Rodriguez A, Duncan R, Pitchenik A, Quintero N, et al. Increased risk of Pneumocystis carinii and community-acquired pneumonia with tobacco use in HIV disease. Int J Infect Dis. 2005;9(4):208–17.
6. Sigel K, Wisnivesky J, Gordon K, Dubrow R, Justice A, Brown ST, et al. HIV as an independent risk factor for incident lung cancer. AIDS. 2012;26(8):1017–25.
7. Helleberg M, Gerstoft J, Afzal S, Kronborg G, Larsen CS, Pedersen C, et al. Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV. AIDS. 2014;28(10):1499–508.
8. Crothers K, Huang L, Goulet JL, Goetz MB, Brown ST, Rodriguez-Barradas MC, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med. 2011;183(3):388–95.
9. Gordin FM, Roediger MP, Girard PM, Lundgren JD, Miro JM, Palfreeman A, et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med. 2008;178(6):630–6.
10. Kohli R, Lo Y, Homel P, Flanigan TP, Gardner LI, Howard AA, et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis. 2006;43(1):90–8.
11. Benard A, Mercie P, Alioum A, Bonnet F, Lazaro E, Dupon M, et al. Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000-2007. PLoS ONE. 2010;5(1):e8896.
12. Fitch KV, Lo J, Abbara S, Ghoshhajra B, Shturman L, Soni A, et al. Increased coronary artery calcium score and noncalcified plaque among HIV-infected men: relationship to metabolic syndrome and cardiac risk parameters. J Acquir Immune Defic Syndr. 2010;55(4):495–9.
13. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010;24(8):1228–30.
14. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec’s public health insurance database. J Acquir Immune Defic Syndr. 2011;57(3):245–53.
15. U.S. Department of Health and Human Services. Tobacco use: prevention, cessation and control. 2006 September 5, 2006.
16. Petoumenos K, Worm S, Reiss P, de Wit S, d’Arminio Monforte A, Sabin C, et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A: D study(*). HIV Med. 2011;12(7):412–21.
17. Triant VA. HIV infection and coronary heart disease: an intersection of epidemics. J Infect Dis. 2012;205(Suppl 3):S355–61.
18. Gritz ER, Vidrine DJ, Lazev AB, Amick BC 3rd, Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res. 2004;6(1):71–7.
19. Niaura R, Shadel WG, Morrow K, Tashima K, Flanigan T, Abrams DB. Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now. Clin Infect Dis. 2000;31(3):808–12.
20. Mamary EM, Bahrs D, Martinez S. Cigarette smoking and the desire to quit among individuals living with HIV. AIDS Patient Care STDS. 2002;16(1):39–42.
21. Centers for Disease Control and Prevention (CDC). Current cigarette smoking among adults-United States, 2011. Morb Mortal Wkly Rep. 2012;61(44):891–4.
22. Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14(4):824–35.
23. Mdodo R, Frazier EL, Dube SR, Mattson CL, Sutton MY, Brooks JT, et al. Cigarette smoking Prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med. 2015;162(5):335–44.
24. Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update Clinical Practice Guideline. Rockville: US Department of Health and Human Services. Public Health Service; 2008.
25. Humfleet GL, Hall SM, Delucchi KL, Dilley JW. A randomized clinical trial of smoking cessation treatments provided in HIV clinical care settings. Nicotine Tob Res. 2013;15(8):1436–45.
26. Gritz ER, Danysh HE, Fletcher FE, Tami-Maury I, Fingeret MC, King RM, et al. Long-term outcomes of a cell phone-delivered intervention for smokers living with HIV/AIDS. Clin Infect Dis. 2013;57(4):608–15.
27. Nahvi S, Cooperman NA. Review: the need for smoking cessation among HIV-positive smokers. AIDS Educ Prev. 2009;21(3 Suppl):14–27.
28. Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation treatments in the United States. Am J Prev Med. 2008;34(2):102–11.
29. Alterman AI, Gariti P, Cook TG, Cnaan A. Nicodermal patch adherence and its correlates. Drug Alcohol Depend. 1999;53(2):159–65.
30. Cooper TV, DeBon MW, Stockton M, Klesges RC, Steenbergh TA, Sherrill-Mittleman D, et al. Correlates of adherence with transdermal nicotine. Addict Behav. 2004;29(8):1565–78.
31. Sabaté E. Adherence to long-term therapies- evidence for action. Switzerland: World Health Organization; 2003.
32. Carroll C, Patterson M, Wood S, Booth A, Rick J, Balain S. A conceptual framework for implementation fidelity. Implement Sci. 2007;30(2):40.
33. Borrelli B. The assessment, monitoring, and enhancement of treatment fidelity in public health clinical trials. J Public Health Dent. 2011;71(s1):S52–63.
34. Hood NE, Ferketich AK, Paskett ED, Wewers ME. Treatment adherence in a lay health adviser intervention to treat tobacco dependence. Health Educ Res. 2013;28(1):72–82.
35. Webb MS, Vanable PA, Carey MP, Blair DC. Medication adherence in HIV-infected smokers: the mediating role of depressive symptoms. AIDS Educ Prev. 2009;21(3 Suppl):94–105.
36. Rao D, Feldman BJ, Fredericksen RJ, Crane PK, Simoni JM, Kitahata MM, et al. A structural equation model of HIV-related stigma, depressive symptoms, and medication adherence. AIDS Behav. 2011;16:711–6.
37. Venkatesh KK, Srikrishnan AK, Mayer KH, Kumarasamy N, Raminani S, Thamburaj E, et al. Predictors of nonadherence to highly active antiretroviral therapy among HIV-infected South Indians in clinical care: implications for developing adherence interventions in resource-limited settings. AIDS Patient Care STDS. 2010;24(12):795–803.
38. Silverberg MJ, Leyden W, Quesenberry CP, Horberg MA. Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. J Gen Intern Med. 2009;24(9):1065–72.
39. Bird ST, Bogart LM, Delahanty DL. Health-related correlates of perceived discrimination in HIV care. AIDS Patient Care STDs. 2004;18(1):19–26.
40. Shuter J, Bernstein SL. Cigarette smoking is an independent predictor of nonadherence in HIV-infected individuals receiving highly active antiretroviral therapy. Nicotine Tob Res. 2008;10(4):731–6.
41. Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58(2):181–7.
42. Gonzalez JS, Psaros C, Batchelder A, Applebaum A, Newville H, Safren SA. Clinician-assessed depression and HAART adherence in HIV-infected individuals in methadone maintenance treatment. Ann Behav Med. 2011;42(1):120–6.
43. Sowah LA, Busse S, Amoroso A. HIV, tobacco use, and poverty: a potential cause of disparities in health status by race and socioeconomic status. J Health Care Poor Underserved. 2013;24(3):1215–25.
44. Shirley DK, Kesari RK, Glesby MJ. Factors associated with smoking in HIV-infected patients and potential barriers to cessation. AIDS Patient Care STDS. 2013;27(11):604–12.
45. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.
46. Hays JT, Leischow SJ, Lawrence D, Lee TC. Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence. Nicotine Tob Res. 2010;12(6):574–81.
47. Crothers K, Thompson BW, Burkhardt K, Morris A, Flores SC, Diaz PT, et al. HIV-associated lung infections and complications in the era of combination antiretroviral therapy. Proc Am Thorac Soc. 2011;8(3):275–81.
48. SRNT Committee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tobacco Res. 2002;4:149–59.
49. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012;4:CD006103.
50. Swan GE, McClure JB, Jack LM, Zbikowski SM, Javitz HS, Catz SL, et al. Behavioral counseling and varenicline treatment for smoking cessation. Am J Prev Med. 2010;38(5):482–90.
51. Food and Drug Administration. The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics): suicidal ideation and behavior. FDA Drug Saf Newsl. 2009;2:1–4.
52. Wewers ME, Ferketich AK, Harness J, Paskett ED. Effectiveness of a nurse-managed, lay-led tobacco cessation intervention among Ohio Appalachian women. Cancer Epidemiol Biomarkers Prev. 2009;18(12):3451–8.
53. Kozlowski LT, Porter CQ, Orleans CT, Pope MA, Heatherton TF. Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, HSI. Drug Alcohol Depend. 1994;34:211–6.
54. Velicer WF, DiClemente CC, Prochaska JO, Brandenburg N. Decisional balance measure for assessing and predicting smoking status. J Pers Soc Psychol. 1985;48(5):1279–89.
55. Beck A, Ward C, Mendelson M, Mock J, Erbaugh J. Inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–71.
56. Ware JE, Kosinski M, Dewey JE, Gandek B. How to score and interpret single-item health status measures: A manual for users of the SF-8 health survey. Lincoln: Quality Metric Inc.; 2001.
57. Roberts B, Browne J, Ocaka KF, Oyok T, Sondorp E. The reliability and validity of the SF-8 with a conflict-affected population in northern Uganda. Health Qual Life Outcomes. 2008;2(6):108.
58. Lefante JJ Jr, Harmon GN, Ashby KM, Barnard D, Webber LS. Use of the SF-8 to assess health-related quality of life for a chronically ill, low-income population participating in the Central Louisiana Medication Access Program (CMAP). Qual Life Res. 2005;14(3):665–73.
59. Bradley KA, Kivlahan DR, Bush KR, McDonell MB, Fihn SD. Variations on the CAGE Alcohol Sreening Questionnaire: strength and limitations in VA general medical patients. Alcohol Clin Exp Res. 2001;25(10):1472–8.
60. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794–811.
61. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–14.
62. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.
63. Pomerleau CS, Pomerleau OF, Majchrzak MJ, Kloska DD, Malakuti R. Relationship between nicotine tolerance questionnaire scores and plasma cotinine. Addict Behav. 1990;15:73–80.
64. Zhou W, Heist RS, Liu G, Park S, Neuberg DS, Asomaning K, et al. Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. Lung Cancer. 2006;53(3):375–80.
65. Hosmer D, Lemeshow S. Applied logistic regression. New York: Wiley; 2000.
66. Pacek LR, Latkin C, Crum RM, Stuart EA, Knowlton AR. Interest in quitting and lifetime quit attempts among smokers living with HIV infection. Drug Alcohol Depend. 2014;1(138):220–4.
67. Ong MK, Zhou Q, Sung HY. Primary care providers advising smokers to quit: comparing effectiveness between those with and without alcohol, drug, or mental disorders. Nicotine Tob Res. 2011;13(12):1193–201.
68. Catz SL, Jack LM, McClure JB, Javitz HS, Deprey M, Zbikowski SM, et al. Adherence to varenicline in the COMPASS smoking cessation intervention trial. Nicotine Tob Res. 2011;13(5):361–8.
69. Balmford J, Borland R, Hammond D, Cummings KM. Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey. Nicotine Tob Res. 2011;13(2):94–102.
70. King G, Polednak A, Bendel RB, Vilsaint MC, Nahata SB. Disparities in smoking cessation between African Americans and Whites: 1990–2000. Am J Public Health. 2004;94(11):1965–71.
71. Daza P, Cofta-Woerpel L, Mazas C, Fouladi RT, Cinciripini PM, Gritz ER, et al. Racial and ethnic differences in predictors of smoking cessation. Subst Use Misuse. 2006;41(3):317–39.
72. Fu SS, Kodl MM, Joseph AM, Hatsukami DK, Johnson EO, Breslau N, et al. Racial/ethnic disparities in the use of nicotine replacement therapy and quit ratios in lifetime smokers ages 25 to 44 years. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1640–7.
73. Carpenter MJ, Ford ME, Cartmell K, Alberg AJ. Misperceptions of nicotine replacement therapy within racially and ethnically diverse smokers. J Natl Med Assoc. 2011;103(9–10):885–94.
74. Lacey L, Tukes S, Manfredi C, Warnecke RB. Use of lay health educators for smoking cessation in a hard-to-reach urban community. J Community Health. 1991;16(5):269–82.
75. Whittaker R, McRobbie H, Bullen C, Borland R, Rodgers A, Gu Y. Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD006611.
76. Mermelstein R, Lichtenstein E, McIntyre K. Partner support and relapse in smoking-cessation programs. J Consult Clin Psychol. 1983;51(3):465–6.
77. Havassy BE, Hall SM, Wasserman DA. Social support and relapse: commonalities among alcoholics, opiate users, and cigarette smokers. Addict Behav. 1991;16(5):235–46.